Randall v. Secretary of Health and Human Services

CourtUnited States Court of Federal Claims
DecidedJanuary 9, 2020
Docket17-803
StatusUnpublished

This text of Randall v. Secretary of Health and Human Services (Randall v. Secretary of Health and Human Services) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Randall v. Secretary of Health and Human Services, (uscfc 2020).

Opinion

In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS No. 17-803V

************************* * * TO BE PUBLISHED CHARLES RANDALL, * * * Special Master Katherine E. Oler Petitioner, * * Filed: July 30, 2019 v. * * * SECRETARY OF HEALTH AND * Attorneys’ Fees & Costs; HUMAN SERVICES, * Reasonable Basis; Tetanus-diphtheria * * (Td) vaccine; Miller-Fisher syndrome Respondent. * (MFS); Guillain Barré syndrome (GBS) * ************************* *

Jessica Olins, Maglio Christopher & Toale, PA, Sarasota, FL for Petitioner.

Lisa A. Watts, U.S. Department of Justice, Washington, D.C., for Respondent.

DECISION ON FINAL ATTORNEYS’ FEES AND COSTS1

On June 14, 2017, Charles Randall (“Petitioner”) filed a petition seeking compensation under the National Vaccine Injury Compensation Program (the “Vaccine Program”)2 alleging that he suffered from the Miller-Fisher variant of Guillain-Barré syndrome (“MFS/GBS”), as a result of the tetanus-diphtheria (“Td”) vaccine he received on September 1, 2015. Pet., ECF No. 1. On March 25, 2019, Petitioner filed a Motion for Decision Dismissing Petition, ECF No. 27, and I issued a decision dismissing the petition for insufficient proof on March 27, 2019, ECF No. 28.

1 This Decision will be posted on the Court of Federal Claims’ website. This means the ruling will be available to anyone with access to the internet. As provided by 42 U.S.C. § 300aa-12(d)(4)(B), however, the parties may object to the decision’s inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to request redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). If, upon review, I agree that the identified materials fit within this definition, I will redact such material from public access. Otherwise, the Decision in its present form will be available. Id. 2 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) (“Vaccine Act” or “the Act”). Individual section references hereafter will be to § 300aa of the Act (but will omit that statutory prefix).

1 On March 28, 2019, Petitioner filed a Motion for Attorneys’ Fees and Costs. Fees App., ECF No. 29. Petitioner requests attorneys’ fees in the amount of $15,345.20 and costs in the amount of $1,457.96, for a total of $16,803.16. Id. at 1-2. In compliance with General Order No. 9, Petitioner submitted a statement representing that “Petitioner did not incur costs related to the litigation of this matter.” Ex. 20, ECF No. 29-3. Respondent submitted his response on April 10, 2019 opposing the motion. Fees Resp., ECF No. 30. For the reasons set forth below, Petitioner’s motion for attorneys’ fees and costs is GRANTED IN FULL.

I. Petitioner’s Medical History Petitioner was 71 years of age at the time of the vaccination at issue, and had a past medical history that included glaucoma, chronic blindness in the left eye, coronary artery disease, myocardial infarction with stent placement, and hypertension. Ex. 2 at 6; Ex. 3 at 8. Petitioner received a Td booster, the allegedly causal vaccination, on September 1, 2015, Ex. 1, after sustaining first and second degree burns to his face and upper extremities, Ex. 10 at 73-76. Petitioner was seen several times throughout September 2015 for follow-up appointments relating to his burn injuries. Ex. 4 at 6-53. Separately, at a glaucoma check-up appointment on September 21, 2015, Petitioner reported a slight decrease in vision without pain. Ex. 17 at 25. Petitioner was next seen at the Gossage Eye Institute on September 29, 2015 complaining of pain and watering in the left eye. Ex. 6 at 11. He was treated for conjunctival and corneal abrasion, and was seen for follow-ups on October 8 and 15, 2015. Id. at 5-10.

On November 2, 2015, Petitioner was seen at the Hillsdale Community Health Center complaining of sudden onset headache, dizziness, difficulty walking, blurry vision, nausea, and generalized weakness that began the previous day. Ex. 10 at 6-27. Petitioner’s history indicated left-eye blindness since childhood and bilateral glaucoma. Id. at 14. Despite being able to detect light, his right eye was immobile and no extraocular movement could be realized. Id. A CT angiogram of Petitioner’s head revealed a 2mm aneurysm of the right supraclinoid internal carotid artery and he was transferred to Borgess Medical Center (“BMC”) for further evaluation. Ex. 5 at 48-50. Petitioner was admitted at BMC from November 3, 2015 until November 11, 2015. Ex. 2 at 5-13; Ex. 5 at 49-52. A neurologic examination showed bilateral oculomotor paralysis. Ex. 2 at 6. Lab tests revealed elevated protein in his cerebrospinal fluid, elevated erythrocyte sedimentation rate, and positive ganglioside antibodies. Ex. 2 at 6, 25, 39, 47. Petitioner was diagnosed with MFS/GBS, and received a five-day course of intravenous immunoglobulin (“IVIG”). Id. at 5-7. Upon discharge, his diagnoses included oculomotor paralysis of both eyes, MFS/GBS, blurred vision in the right eye, blindness in the left eye, unsteady gait, and glaucoma. Id. at 5-6.

Petitioner was seen for follow-up at Michigan State University’s Department of Neurology and Ophthalmology (“MSU”) on December 21, 2015. Ex. 5 at 13-18. Petitioner indicated at this visit that he had experienced a decrease in vision in his right eye three months prior (September 2015), but that his ophthalmologist told him it was within normal limits. Id. at 14. The impression was opthalmoplegia and MFS/GBS with improvement following IVIG. Id. On January 12, 2016, Petitioner was seen for follow-up in the Hillsdale Neurology Clinic. Ex. 7 at 2. His exam showed full ocular motion with sensitivity to light and brisk pupillary response in the right eye. Id. at 2-5. Petitioner stated that his gait had not fully recovered, and while it was noted that he had difficulty

2 performing a tandem gait maneuver, it was also noted that this was not unusual for someone 71 years of age. Ex. 7 at 2-5. The neurologist noted pneumococcal and shingles vaccinations in June and July 2015, but stated that while there was some literature linking those vaccines to “cross immune” reactions, it was unlikely that they would affect Petitioner in November 2015. Id. at 4. The Td vaccine was not mentioned. Id. The impression was that Petitioner had made a good recovery from presumed MFS/GBS. Id. at 5.

On March 21, 2016, Petitioner was seen at MSU for follow-up of his MFS/GBS, eye paralysis, and blurred vision. Ex. 13 at 2. The impression was ophthalmoplegia and MFS/GBS with near full recovery of right ophthalmoplegia. Id.

On May 9, 2016, Petitioner was seen by his primary care physician, Dr. Robert Schall, for a painful rash on his back and chest and was assessed with herpes zoster (shingles) without complications. Ex. 12 at 5-6, 8. The record from this visit notes “Miller-[F]isher [s]yndrome” under “Active Problems,” and lists “T[dap]3 vaccine” under “Allergies.” Id. at 5-6. Petitioner was seen for follow-up appointments on June 22, 2016, Id. at 9-14, December 22, 2016, Id. at 15-20, and June 19, 2017, Id. at 21-28. Each of these visits noted MFS/GBS and the Tdap vaccine allergy, but also noted that Petitioner’s MFS/GBS was possibly secondary to the pneumonia or flu vaccine, as well as noting residual third nerve palsy and gait disorder from ataxia.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Blum v. Stenson
465 U.S. 886 (Supreme Court, 1984)
Avera v. Secretary of Health and Human Services
515 F.3d 1343 (Federal Circuit, 2008)
Chuisano v. Secretary of Health and Human Services
116 Fed. Cl. 276 (Federal Claims, 2014)
Raymo v. Secretary of Health and Human Services
129 Fed. Cl. 691 (Federal Claims, 2016)
Simmons v. Secretary of Health & Human Services
875 F.3d 632 (Federal Circuit, 2017)
Grice v. Secretary of Health & Human Services
36 Fed. Cl. 114 (Federal Claims, 1996)
Savin v. Secretary of Health & Human Services
85 Fed. Cl. 313 (Federal Claims, 2008)
McKellar v. Secretary of Health & Human Services
101 Fed. Cl. 297 (Federal Claims, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Randall v. Secretary of Health and Human Services, Counsel Stack Legal Research, https://law.counselstack.com/opinion/randall-v-secretary-of-health-and-human-services-uscfc-2020.